WO2021054535A3 - Composition pharmaceutique contenant de l'efinaconazole stabilisée comprenant une combinaison d'un agent chélatant, d'un antioxydant et d'un acide - Google Patents

Composition pharmaceutique contenant de l'efinaconazole stabilisée comprenant une combinaison d'un agent chélatant, d'un antioxydant et d'un acide Download PDF

Info

Publication number
WO2021054535A3
WO2021054535A3 PCT/KR2019/017074 KR2019017074W WO2021054535A3 WO 2021054535 A3 WO2021054535 A3 WO 2021054535A3 KR 2019017074 W KR2019017074 W KR 2019017074W WO 2021054535 A3 WO2021054535 A3 WO 2021054535A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
antioxidant
acid
chelating agent
combination
Prior art date
Application number
PCT/KR2019/017074
Other languages
English (en)
Korean (ko)
Other versions
WO2021054535A2 (fr
Inventor
김범준
구교탄
Original Assignee
주식회사 바이오빌리프
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190125949A external-priority patent/KR20210032869A/ko
Application filed by 주식회사 바이오빌리프 filed Critical 주식회사 바이오빌리프
Publication of WO2021054535A2 publication Critical patent/WO2021054535A2/fr
Publication of WO2021054535A3 publication Critical patent/WO2021054535A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour administration topique, sous la forme d'une solution contenant de l'efinaconazole, comprenant une combinaison spécifique d'un agent chélatant, d'un antioxydant et d'un acide. La composition pharmaceutique de la présente invention présente une excellente stabilité physico-chimique.
PCT/KR2019/017074 2019-09-17 2019-12-05 Composition pharmaceutique contenant de l'efinaconazole stabilisée comprenant une combinaison d'un agent chélatant, d'un antioxydant et d'un acide WO2021054535A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2019-0113983 2019-09-17
KR20190113983 2019-09-17
KR1020190125949A KR20210032869A (ko) 2019-09-17 2019-10-11 킬레이트화제, 항산화제, 및 산의 조합을 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR10-2019-0125949 2019-10-11

Publications (2)

Publication Number Publication Date
WO2021054535A2 WO2021054535A2 (fr) 2021-03-25
WO2021054535A3 true WO2021054535A3 (fr) 2021-05-14

Family

ID=74884655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/017074 WO2021054535A2 (fr) 2019-09-17 2019-12-05 Composition pharmaceutique contenant de l'efinaconazole stabilisée comprenant une combinaison d'un agent chélatant, d'un antioxydant et d'un acide

Country Status (1)

Country Link
WO (1) WO2021054535A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317695A1 (en) * 2006-12-28 2010-12-16 Tomohiro Okumura Gel composition for treating mycosis
KR20140072016A (ko) * 2011-06-24 2014-06-12 아쿠아 바이오 테크놀로지 에이에스에이 연어과 알류의 부화액으로부터 화장료 조성물을 제조하는 방법 및 피부의 미용 외모를 개선시키기 위한 이의 용도
KR20160068812A (ko) * 2013-10-03 2016-06-15 다우 파마슈티컬 사이언시즈, 인코포레이티드 안정화된 에피나코나졸 조성물
KR20160087898A (ko) * 2013-11-22 2016-07-22 다우 파마슈티컬 사이언시즈, 인코포레이티드 항­감염 방법，조성물，및 장치
WO2018110693A1 (fr) * 2016-12-16 2018-06-21 株式会社カネカ Agent thérapeutique contre l'onychomycose

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317695A1 (en) * 2006-12-28 2010-12-16 Tomohiro Okumura Gel composition for treating mycosis
KR20140072016A (ko) * 2011-06-24 2014-06-12 아쿠아 바이오 테크놀로지 에이에스에이 연어과 알류의 부화액으로부터 화장료 조성물을 제조하는 방법 및 피부의 미용 외모를 개선시키기 위한 이의 용도
KR20160068812A (ko) * 2013-10-03 2016-06-15 다우 파마슈티컬 사이언시즈, 인코포레이티드 안정화된 에피나코나졸 조성물
KR20160087898A (ko) * 2013-11-22 2016-07-22 다우 파마슈티컬 사이언시즈, 인코포레이티드 항­감염 방법，조성물，및 장치
WO2018110693A1 (fr) * 2016-12-16 2018-06-21 株式会社カネカ Agent thérapeutique contre l'onychomycose

Also Published As

Publication number Publication date
WO2021054535A2 (fr) 2021-03-25

Similar Documents

Publication Publication Date Title
WO2016149028A3 (fr) Formulations d'épinéphrine
WO2019120234A3 (fr) Composé fonctionnant comme inhibiteur de protéine bromodomaine, et composition
EP1312366A8 (fr) Compositions pharmaceutiques aqueuses
WO2007100382A3 (fr) Préparations de gallium administrables per os et leurs méthodes d'utilisation
MX2021002981A (es) Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).
MX2019003099A (es) Composicion farmaceutica.
MX2020011873A (es) Nuevos derivados de quinolina.
WO2021062231A3 (fr) Composés de promédicament cannabinoïde
CA3037257C (fr) Compositions pharmaceutiques comprenant du dipropionate de beclomethasone et du fumarate de formoterol dihydrate
MX2021014680A (es) Derivado de benzotriazol.
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
WO2006072070A3 (fr) Formulations pharmaceutiques contenant des sels de gallium
EP4289478A3 (fr) Composition pharmaceutique d'edaravone
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
WO2019203771A3 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la sitagliptine
MX2022003504A (es) Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo.
PH12017502322A1 (en) Therapeutic agent for fibrosis
EP4028059A4 (fr) Compositions médicinales stables de cannabidiol
PH12021550389A1 (en) Pharmaceutical composition comprising antiplatelet agent and gastric acid secretion inhibitor
MX2022007707A (es) Comprimidos de edoxaban.
WO2007087026A3 (fr) Forme solide de amg 706 et compositions pharmaceutiques contenant ledit composé
EP3964520A4 (fr) Nouvel oligopeptide et composition pharmaceutique pour prévenir ou traiter le cancer contenant ledit composé comme principe actif
EP3981389A4 (fr) Composition pharmaceutique administrée par voie topique sous forme de solution contenant de l'éfinaconazole
WO2018097570A3 (fr) Formulation pharmaceutique comprenant de la l-proline de dapagliflozine
EP4223759A4 (fr) Composé pyrazolopyridazinone, composition pharmaceutique le contenant et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19945787

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19945787

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 19945787

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 14/09/2022)

122 Ep: pct application non-entry in european phase

Ref document number: 19945787

Country of ref document: EP

Kind code of ref document: A2